TrialNature medicine2025

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.

Reinhard Dummer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.